Abbott launched the first OTC continuous glucose monitor in the U.S.

Abbott Laboratories has launched its first over-the-counter continuous glucose monitor (CGM) in the United States. This innovative device, Lingo, is designed to help individuals track their glucose levels without a prescription.

The Lingo CGM is a significant advancement in diabetes management. Providing real-time glucose readings empowers individuals to make informed decisions about their diet, exercise, and overall health. Previously, access to continuous glucose monitoring was restricted to individuals with diabetes who required insulin therapy.

The availability of Lingo as an over-the-counter product is expected to broaden its appeal and increase its accessibility. Individuals interested in monitoring their glucose levels for general health and wellness purposes can purchase Lingo without a doctor’s prescription.

Abbott’s launch of Lingo comes amid growing interest in wearable health technology. Continuously tracking glucose levels offers individuals valuable insights into their health and can help them make informed lifestyle choices.

The availability of Lingo is a positive development for individuals seeking to improve their health and well-being. It represents a significant step forward in diabetes management and wearable technology.